$MPLT News

Down 29.2% in 4 Weeks, Here's Why You Should You Buy the Dip in MapLight Therapeutics, Inc. (MPLT)

Down 34.8% in 4 Weeks, Here's Why MapLight Therapeutics, Inc. (MPLT) Looks Ripe for a Turnaround

MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics

Guggenheim Initiates Coverage On MapLight Therapeutics with Neutral Rating

MapLight Therapeutics Files Prospectus Related To The Resale Of Up To 13,181,055 Common Shares By Selling Stockholders

MapLight Therapeutics to Participate in Upcoming Investor Conference

Needham Maintains Buy on MapLight Therapeutics, Lowers Price Target to $43

MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

MapLight Therapeutics Launching $150 Million Private Placement Financing

MapLight Therapeutics Announces $150 Million Private Placement Financing

MapLight Therapeutics Enters Securities Purchase Agreement For $150M Private Placement Financing

UBS Downgrades MapLight Therapeutics to Neutral, Lowers Price Target to $13

MapLight Therapeutics stock crashes on Phase II schizophrenia data

Canaccord Genuity Maintains Buy on MapLight Therapeutics, Lowers Price Target to $24

Morgan Stanley Downgrades MapLight Therapeutics to Equal-Weight, Lowers Price Target to $21

MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Results of Phase 2 ZEPHYR Study of ML-007C-MA in Schizophrenia Transcript

HC Wainwright & Co. Maintains Buy on MapLight Therapeutics, Lowers Price Target to $26

MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Results of Phase 2 ZEPHYR Study of ML-007C-MA in Schizophrenia - Slideshow

MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose

Maplight Therapeutics’ Schizophrenia Drug Hits Phase II Primary Endpoint